Category: elsevier

Journal republishes withdrawn paper on emergency care prices, amid controversy

The Annals of Emergency Medicine has republished a controversial paper it withdrew earlier this year which compared the cost of emergency care at different types of facilities.

Because the paper drew heavy criticism when it was originally released, the journal has published a revised version, along with several editorials and discussions between the authors and critics. One point of contention: The analysis stems from data provided by an insurance company — Blue Cross Blue Shield — which it declined to share.

The paper — originally published in February —  caught national attention (and raised concerns among some emergency care providers) when it reported the cost of treatment in emergency departments can be significantly higher than at urgent care centers, even for the same conditions. The journal withdrew the paper in spring, and re-published it Tuesday, with minor changes.

First author Vivian Ho at Rice University told us she made “slight changes”  to some headings, phrases, and the appendix, but:

Continue reading Journal republishes withdrawn paper on emergency care prices, amid controversy

Journal knew about problems in a high-profile study before it came out — and did nothing for over a month

In June, Gene Emery, a journalist for Reuters Health, was assigned to write a story about an upcoming paper in the Journal of the American College of Cardiology, set to come off embargo and be released to the public in a few days. Pretty quickly, he noticed something seemed off.

Emery saw that the data presented in the tables of the paper — about awareness of the problem of heart disease among women and their doctors — didn’t seem to match the authors’ conclusions. For instance, on a scale of 1 to 5 rating preparedness to assess female patients’ risk (with 5 being the most prepared), 64% of doctors answered 4 or 5; but the paper said “only a minority” of doctors felt well-prepared (findings echoed in an accompanying press release). On Monday June 19, four days before the paper was set to publish, Emery told the corresponding author — C. Noel Bairey Merz, Medical Director of the Women’s Heart Center at Cedars-Sinai in Los Angeles — about the discrepancy; she told him to rely on the data in the table.

But the more Emery and his editors looked, the more problems they found with the paper. They alerted the journal hours before it was set to publish, hoping that was enough to halt the process. It wasn’t.

Continue reading Journal knew about problems in a high-profile study before it came out — and did nothing for over a month

Curious: A paper’s acknowledgments harshly criticized Spanish gov’t funding. Now two authors object.

In 2014, researchers condemned the Spanish Government for “destroying the R&D horizon of Spain and the future of a complete generation” in the acknowledgment section of a paper about wireless networks.

Three years later, the two last authors of the paper are protesting that protest, issuing a correction to alert readers that they did not approve the language. Here’s the text of the corrigendum notice, which mentions Juan M. Górriz and Javier Ramírez, both based at University of Granada: Continue reading Curious: A paper’s acknowledgments harshly criticized Spanish gov’t funding. Now two authors object.

Genetic disorder gets name change, but patient’s father still not happy

Credit: Online Mendelian Inheritance in Man

The leading genetic disease database has chosen a new name for a genetic condition, following complaints from a man whose son has the condition.

On Aug. 11, 2017, two days after our coverage of the situation, the Online Mendelian Inheritance in Man (OMIM) database changed the primary name of the phenotype associated with mutations in the RPS23 gene. The new name describes a set of features: “Brachycephaly, Trichomegaly, and Developmental Delay,” or BTDD.

Brachycephaly describes a condition where the back of the head is abnormally flat and trichomegaly refers to extra length, curling, pigmentation, or thickness of the eyelashes.

Marc Pieterse, of the Netherlands, has a son with the rare RPS23 mutation, one of two known patients in the world. The mutation affects ribosomes, cell components involved in protein production. On Aug. 9, we reported on Pieterse’s crusade against OMIM’s original name for the condition, which dubbed it a syndrome. He has feared that calling it a syndrome would “stigmatize” his son’s condition and tried to get the paper underpinning the OMIM entry retracted. The American Journal of Human Genetics has said it will not retract the paper.

Continue reading Genetic disorder gets name change, but patient’s father still not happy

Elsevier retracts entire issue after mistakenly publishing it online

Publishing giant Elsevier has retracted an entire issue of one of its journals because the contents — abstracts from a conference about child neurology — were never supposed to make it online.

We discovered the retraction after realizing that every aspect of the issue in Brain & Development had been retracted, including the cover, editorial board, and the contents.

We contacted Elsevier, and a spokesperson told us:

Continue reading Elsevier retracts entire issue after mistakenly publishing it online

Fearing “stigmatization,” patient’s father seeks retraction of paper on rare genetic mutation

The father of a boy with a rare genetic mutation has accused a scientist of exploiting his child by proclaiming the defect a “genetic syndrome” and naming it after herself.

At an impasse with scientists investigating, publicizing, and interpreting his son’s condition, the father seems willing to use any leverage he can muster to remove the “syndrome” entry in an online genetic disease database. Based solely on an email he obtained from the database director, the father became convinced that if the paper underpinning the entry were retracted, the syndrome would go down with it. So earlier this year, he withdrew his consent and asked the journal that published the paper for a retraction, based on improper patient consent. He has also threatened to lob accusations of research misconduct at the paper’s last author. Continue reading Fearing “stigmatization,” patient’s father seeks retraction of paper on rare genetic mutation

The three-year delay: Journal finally retracts paper based on made-up data

Three years after an investigation revealed a 2013 paper was based on fraudulent data, a journal has finally retracted it.

The paper, published in Journal of Hazardous Materials, was one of seven articles by a team at the Institute of Microbial Technology (IMTECH) in Chandigarh, India that contain fabricated data, according to an investigation by the Council of Scientific and Industrial Research in New Delhi. (IMTECH is part of the Council of Scientific and Industrial Research.) Although it took one journal years to take action, another still has not retracted one of the seven flagged papers. Continue reading The three-year delay: Journal finally retracts paper based on made-up data

After investigation that started at least 5 years ago, retired ob-gyn prof agrees to 5 years of supervision

Nasser Chegini

A now-retired professor tweaked the findings in seven figures of a 2007 paper, according to a new finding of misconduct released yesterday by the U.S. Office of Research Integrity.

The subject of the findings isn’t a stranger to our readers: We’ve already reported on nine retractions for Nasser Chegini, a former professor of obstetrics and gynecology at the University of Florida (UF) who had won more than $4 million in Federal grants. And Chegini, who retired in early 2012, had been under investigation since at least 2012, with the ORI asking UF to broaden that investigation at one point.

Indeed, the ORI’s notice states that eight of Chegini’s retractions resulted from the UF’s investigation. The ORI’s findings, however, stem from another paper, published in the Journal of Reproductive Immunology, which has not been retracted.

According to the ORI, in that paper, Chegini:

Continue reading After investigation that started at least 5 years ago, retired ob-gyn prof agrees to 5 years of supervision

Why did it take a journal two years to retract a paper after a misconduct finding?

A 2014 paper containing data manipulated by a former graduate student has finally been retracted, two years after the U.S. Office of Research Integrity (ORI) published its findings.

In August 2015, the ORI published a report that Peter Littlefield, who was working on his PhD at the University of California, San Francisco (UCSF), had committed “research misconduct by falsifying and/or fabricating data” in two papers. Littlefield agreed to correct or retract the papers–one published in Chemistry & Biology and the other in Science Signaling.  

When we contacted Chemistry & Biology back in August 2015, a spokesperson for Cell Press told us the journal was figuring out “the best way to correct the scientific record.”

Apparently that took two years. In the meantime, the journal did not issue an expression of concern or otherwise notify readers of the issues. Continue reading Why did it take a journal two years to retract a paper after a misconduct finding?